Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus VANDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V RTU IN PLASTIC CONTAINER versus VANDAZOLE.
FLAGYL I.V. RTU IN PLASTIC CONTAINER vs VANDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
VANDAZOLE is a nitroimidazole antimicrobial agent that undergoes reduction by bacterial nitroreductases, forming cytotoxic free radicals that damage DNA and inhibit nucleic acid synthesis.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
2 g orally as a single dose once daily for 2 days.
None Documented
None Documented
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Approximately 8-10 hours in adults; prolonged to 20-25 hours in hepatic impairment.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
Primarily renal (40-70% unchanged), with biliary/fecal elimination accounting for 15-20% as metabolites.
Category C
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic